PURPOSE:To evaluate prospectively the efficacy of treating thrombosed hemodialysis arteriovenous polytetrafluoroethylene (PTFE) grafts using tissue-type plasminogen activator (tPA) and percutaneous transluminal angioplasty (PTA).MATERIALS AND METHODS:Forty-two sequential thrombosed PTFE dialysis grafts in 33 patients presented for declotting. All 42 grafts were treated with a modified lysis and PTA technique with use of 2 mg tPA and 3,000-5,000 U heparin in a total volume of 5 mL, administered into the graft via an angiocatheter. The elapsed time from tPA injection until completion was recorded. Prospective data collection included demographic information, technical details of the procedure, immediate outcomes, complications, and patency rates.RESULTS:Technical success, defined as complete graft recanalization with a palpable thrill after treatment plus successful hemodialysis, was achieved in all cases, except five. These five cases were deliberate graft closures due to inadequacy of the outflow veins to support an arteriovenous graft after successful lysis. Mean lysis time was 40.8 minutes and mean room procedure time after the lysis period was 65.4 minutes. Eight procedure-related complications occurred (two major and six minor). The follow-up period was 4-241 days, with an estimated mean of 157 days. The 30-day and 90-day primary patency rates were 57% and 50%, respectively.CONCLUSIONS:Treatment of thrombosed PTFE dialysis grafts with use of 2 mg tPA and 3,000 U of heparin is safe and effective. Use of this modified lysis and PTA technique allows an expeditious procedure in the angiography suite. However, this technique precludes imaging of the outflow veins before treatment, so that grafts entering diffusely diseased veins may need to be closed after successful lysis.
In 1994, an Army medical clinic reported a problem during attempts to resuscitate an infant. The FDA's investigation discovered that the expiratory channel had become occluded after a lubricant was...
This article outlines several aspects of sleep regulation relevant to pediatric pain management. A broad range of connections between sleep and pain are described: (1) pain can interfere with the quality and quantity of children's sleep; (2) insufficient sleep (quality or quantity) can cause daytime sequelae (behavioral and emotional changes) that interfere with the coping skills necessary for effective pain management; (3) fear and anxiety often have a negative impact on both pain and sleep; (4) feelings of safety and control frequently have a positive effect on both sleep and pain symptoms; (5) adequate sleep seems to promote both physiological (tissue repair) and psychological (transient cessation of the perception of pain signals) processes relevant to recovery from pain, injury, and illness; and (6) treatment approaches to pediatric sleep and pain problems show considerable overlap with respect to many pharmacological as well as cognitive-behavioral interventions. Given these multiple links, a better understanding of sleep--and its importance in physical and mental health--is likely to be of value to clinicians and researchers working in areas of pediatric pain management. One specific hypothesis to be addressed is the possible contribution of sleep disruption as a step in the progression to some chronic pain syndromes.
PURPOSE:To review the effects of heparin and heparinoid compounds on aldosterone physiology and associated induction of hyperkalemia. MATERIALS AND METHODS:A comprehensive literature search (of human and animal data) was carried out by computer and by using reference citations from primary sources. RESULTS:Heparin and its congeners are predictable, potent inhibitors of aldosterone production. This inhibitory effect is specific for the zona glomerulosa; other corticosteroids are not affected. Aldosterone suppression occurs within a few days of initiation of therapy, is reversible, and is independent of either anticoagulant effect or route of administration. Decreases in aldosterone levels may occur with heparin dosages as low as 5,000 U BID. The most important, but probably not the only mechanism of aldosterone inhibition appears to involve reduction in both the number and affinity of the angiotensin-II receptors in the zona glomerulosa. Prolonged use of heparin causes marked reduction in the width of the adrenal zona glomerulosa. CONCLUSIONS:Aldosterone suppression results in natriuresis and less predictably in decreased excretion of potassium. Greater than normal serum potassium levels occur in about 7% of patients, but marked hyperkalemia generally requires the presence of additional factors perturbing potassium balance (in particular, renal insufficiency, diabetes mellitus, or the use of certain medications). Heparin-induced increases in serum potassium need to be better anticipated by clinicians. Serum potassium levels should be monitored periodically in patients being given heparin for 3 or more days, and in patients at relatively high risk for hyperkalemia, the monitoring interval should probably be no greater than 4 days.
Central venous catheters (CVCs) are essential for many hospitalized patients, but they are associated with important infectious complications. Recent studies have indicated that CVCs coated with antimicrobial agents reduce the incidence of catheter-related bloodstream infection (CR BSI). To estimate the clinical and economic consequences of short-term central venous catheter-related infection and the potential usefulness of antimicrobial-coated catheters, we reviewed and synthesized the available relevant literature. Statistical pooling was used to estimate the incidence of both catheter colonization and CR BSI. The attributable mortality of CR BSI was also evaluated. In addition, the economic consequences of both local and systemic catheter-related infection was estimated from literature reports that used micro-costing and other techniques. Among patients in whom standard, noncoated CVCs are in place for an average of 8 days, 24.7% are expected to develop catheter colonization (95% confidence interval [CI(95)], 22.0%-27.5%). Approximately 5.2% (CI(95), 3.9%-6.5%) will develop CR BSI. The attributable mortality of CR BSI remains unclear, but recent studies are consistent with a range from 4% to 20%. An episode of local catheter-related infection leads to an additional cost of approximately $400, whereas the additional cost of CR BSI ranges from approximately $6,005 to $9,738. Formal economic analyses indicate that CVCs coated with antibacterial agents (such as chlorhexidine-silver sulfadiazine or minocycline-rifampin) likely reduce infectious complications, yielding economic advantages. In light of the substantial clinical and economic burden of catheter-related infection, hospital personnel should adopt proven cost-effective methods to reduce this common and important nosocomial complication.
Indwelling vascular catheters are a major cause of nosocomial sepsis. Prevention of colonization of polymeric surfaces by continuous release of bactericidal, highly biocompatible antimicrobials incorporated into polymers has been investigated as a promising new approach. An antimicrobial polyurethane catheter was investigated by HPLC and various antimicrobial assays. Controlled drug delivery governed by the physico-chemical mass transfer from the polyurethane bulk provided long-term release of the antimicrobial substances from the material to the outer surface and catheter lumen. The in vitro activity of catheters coated with miconazole and rifampicin against 158 clinical isolates of catheter-associated infections was evaluated. Incubated in physiological NaCl at 37 degrees C, the half-life of inhibitory activity of catheters coated with miconazole or rifampicin exceeded 3 weeks. In static and dynamic adhesion assays, coated catheters were able to prevent colonization with Staphylococcus aureus, Staphylococcus epidermidis and enterococci. To produce catheters resistant to infection, a potent antimicrobial efficacy combined with an excellent biocompatibility over time is needed. The long lasting efficacy of the antimicrobial polyurethane alloy as well as the increased antifungal activity of miconazole combined with rifampicin may be regarded as a promising improvement for long-term central venous access.
OBJECTIVE To determine the frequency of central venous catheter-induced thrombosis of the axillary vein. DESIGN Prospective, controlled study. SETTING Tertiary care university center. PATIENTS Sixty patients in a medical-surgical intensive care unit who required central venous catheterization via the axillary vein. INTERVENTIONS Single-lumen, silicone elastomer or polyurethane catheters were inserted for a mean duration of 14.7+/-7.4 days (range, 4-33 days). On catheter removal, bilateral upper-extremity phlebographic examination was performed in each patient. The incidence of deep vein thrombosis in catheterized arms was compared with that in uncatheterized arms. MEASUREMENTS AND MAIN RESULTS Of the 60 patients who underwent axillary vein cannulation, one patient had clinical signs of arm vein thrombosis, but no patient had clinical sign of pulmonary embolism. There were 35 patients (58.3%) who developed positive phlebographic examinations homolateral to the catheter. Fibrin sleeves that developed around the catheters were observed in 28 patients (47%). Five patients (8.3%) had phlebographic signs of partial axillary vein thrombosis: nonobstructive clots adherent to the vessel wall and/or the catheter. Two patients (3.3%) had phlebographic signs of complete axillary vein thrombosis. No thrombosis was observed in patients with catheterizations lasting < or =6 days, two cases were observed for duration of 7-14 days, and five cases were observed for duration of > or =15 days (p < .01). In the seven patients with axillary vein thrombosis, the vessel was cannulated with fewer than three puncture attempts, and the mean duration for catheter insertion (10+/-2.5 min) was not different from that of patients with no axillary vein thrombosis (14+/-9 min). CONCLUSIONS Based on the data from the present study, we conclude that axillary vein catheterization is associated with a 11.6% frequency of upper-extremity deep vein thrombosis. This rate of vein thrombosis is similar to that observed after internal jugular or subclavian vein cannulation. Given the acceptable rate of this clinically important complication, axillary vein cannulation offers an attractive alternative site for catheter insertion to the internal jugular or subclavian vein in the critically ill. Because thrombosis is rare or absent in catheterizations lasting <15 days, it seems wise to withdraw axillary catheters after a maximum of 2 wks.
Cost reduction is a major focus of healthcare in the United States (US) and throughout the world. US hospitals are merging and downsizing staff as a major effort in cost containment. Specialty care teams such as nutrition support, IV therapy, and infection control, have been early prey to downsizing or elimination by administrators who perceive these programs as dispensible amenities. This will most likely prove to be counterproductive and excessively costly. In 1994, the US Agency for Healthcare Policy and Research published The National Bill for Diseases Treated in the U. S. Hospitals, which listed medical complications from the use of a device or procedure for diagnosis or treatment among the top ten most costly health-related problems in the US, at an annual cost of $3.1 billion. An extraordinary number of medical devices are used in the delivery of parenteral and enteral nutrition. Both modalities carry significant risk for costly complications related to the associated medical device. The incidence of central venous catheter (CVC) complications alone is estimated at well over 10%. The consequences of adverse events with vascular catheters and enteral feeding devices can be life-threatening. Patients may survive elaborate, high-tech surgical procedures after trauma or lifethreatening illnesses only to later suffer or die as a result of insufficient knowledge of prevention or treatment of medical device-related complications, or failure of the device itself. Patients surviving such adverse events may be left with profound abnormalities such as neurological impairment, disfigurement, loss of limb, or permanent loss of venous access sites; all negative outcomes which result in extended length of hospital stay and inordinate costs. Another costly and unfortunate outcome of device-related adverse events is malpractice litigation, not typically a line-item in a hospital’s or agency’s budget. Following are examples of recent legal cases where large sums were awarded for patients who suffered or died from such events.
Nutrition in Clinical PracticeVolume 14, Issue 4 p. 165-169 Article The Future of Vascular Access: Will the Benefits Be Worth the Risk? Marcia Ryder, Marcia Ryder Department of Physiological Nursing, University of California, San FranciscoSearch for more papers by this author Marcia Ryder, Marcia Ryder Department of Physiological Nursing, University of California, San FranciscoSearch for more papers by this author First published: 01 August 1999 https://doi.org/10.1177/088453369901400402Citations: 6AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume14, Issue4August 1999Pages 165-169 RelatedInformation
The predominance of elemental iodine as a chemical antiseptic has been established during a century. Free iodine is effective for treatment and prevention of infection. Iodophors, such as povidone-iodine, have replaced elemental iodine in clinical use. Toxic absorption of povidone-iodine occurs from all tissues except intact adult skin, to which its use should be restricted. Povidone-iodine binds iodine so firmly that insufficient free iodine is released to be effective for treating or preventing infection. It is a weak antiseptic that is marginally acceptable as a disinfectant for adult skin. The shortcomings of povidone-iodine stimulated a search for iodophors that would liberate therapeutically effective concentrations of free iodine. These investigations led to a new self-sterilizing plastic formed by the complexing of polyurethane and iodine.
